Physician profile
Robert Murphy
NPI 1356381982
$3,512.07
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $392 · 2021: $989 · 2022: $873 · 2023: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,111.38 | 2019-2023 | |
| Braintree Laboratories, INC. | $512.46 | 2019-2022 | |
| Janssen Biotech, INC. | $475.77 | 2019-2023 | Stelara |
| Pfizer INC. | $253.88 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.27 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $177.29 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $104.96 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $101.40 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.70 | 2019-2023 | Xifaxan |
| Celgene Corporation | $90.59 | 2021-2023 | |
| Redhill Biopharma INC. | $87.26 | 2021 | |
| Merck Sharp & Dohme LLC | $84.64 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $69.98 | 2022-2023 | Dupixent |
| Allergan, INC. | $34.72 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $30.15 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $21.13 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2023 | Cyltezo |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.